CN107233750B - A kind of preparation method of DNA paper folding biological chromatography column and its application in drug screening - Google Patents
A kind of preparation method of DNA paper folding biological chromatography column and its application in drug screening Download PDFInfo
- Publication number
- CN107233750B CN107233750B CN201710401978.2A CN201710401978A CN107233750B CN 107233750 B CN107233750 B CN 107233750B CN 201710401978 A CN201710401978 A CN 201710401978A CN 107233750 B CN107233750 B CN 107233750B
- Authority
- CN
- China
- Prior art keywords
- silica gel
- paper folding
- dna
- target spot
- dna paper
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000004587 chromatography analysis Methods 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 238000007877 drug screening Methods 0.000 title claims abstract description 20
- 108020004414 DNA Proteins 0.000 claims abstract description 166
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 103
- 239000000741 silica gel Substances 0.000 claims abstract description 61
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 61
- 150000001875 compounds Chemical class 0.000 claims abstract description 59
- 102000053602 DNA Human genes 0.000 claims abstract description 26
- 238000001291 vacuum drying Methods 0.000 claims abstract description 26
- 239000000243 solution Substances 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 18
- 108020004682 Single-Stranded DNA Proteins 0.000 claims abstract description 17
- 239000007853 buffer solution Substances 0.000 claims abstract description 9
- 238000006073 displacement reaction Methods 0.000 claims abstract description 9
- 239000012530 fluid Substances 0.000 claims abstract description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 48
- 239000012501 chromatography medium Substances 0.000 claims description 19
- 239000007791 liquid phase Substances 0.000 claims description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- -1 γ-aminopropyl Chemical group 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 14
- 229910001220 stainless steel Inorganic materials 0.000 claims description 12
- 239000010935 stainless steel Substances 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 239000003292 glue Substances 0.000 claims description 10
- 239000002086 nanomaterial Substances 0.000 claims description 10
- 229910052710 silicon Inorganic materials 0.000 claims description 10
- 239000010703 silicon Substances 0.000 claims description 10
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims description 9
- 102000006240 membrane receptors Human genes 0.000 claims description 9
- 108020004084 membrane receptors Proteins 0.000 claims description 9
- 102000006255 nuclear receptors Human genes 0.000 claims description 9
- 108020004017 nuclear receptors Proteins 0.000 claims description 9
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 125000003368 amide group Chemical group 0.000 claims description 8
- 238000005576 amination reaction Methods 0.000 claims description 8
- 238000000137 annealing Methods 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 8
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 8
- 238000011049 filling Methods 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 229940014800 succinic anhydride Drugs 0.000 claims description 8
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 8
- 239000012498 ultrapure water Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 claims description 6
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims 3
- 229910000077 silane Inorganic materials 0.000 claims 3
- 206010013786 Dry skin Diseases 0.000 claims 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- CWAFVXWRGIEBPL-UHFFFAOYSA-N ethoxysilane Chemical compound CCO[SiH3] CWAFVXWRGIEBPL-UHFFFAOYSA-N 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 5
- 230000000857 drug effect Effects 0.000 abstract description 3
- 239000012901 Milli-Q water Substances 0.000 abstract 1
- 239000008119 colloidal silica Substances 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 19
- 229940079593 drug Drugs 0.000 description 15
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 8
- 102000004882 Lipase Human genes 0.000 description 8
- 108090001060 Lipase Proteins 0.000 description 8
- 239000004367 Lipase Substances 0.000 description 8
- 229960001138 acetylsalicylic acid Drugs 0.000 description 8
- 235000019421 lipase Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- XDQITMCFPPPMBC-TUANDBMESA-N scutelloside Natural products OC[C@H]1O[C@@H](O[C@@H]2O[C@@H]3C[C@H]4[C@H](O)[C@@H](O)[C@@](O)(CO3)[C@@H]24)[C@H](O)[C@@H](O)[C@@H]1O XDQITMCFPPPMBC-TUANDBMESA-N 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 229910000831 Steel Inorganic materials 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000010959 steel Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- WCDYMMVGBZNUGB-ORPFKJIMSA-N [(2r,3r,4s,5r,6r)-6-[[(1r,3r,4r,5r,6r)-4,5-dihydroxy-2,7-dioxabicyclo[4.2.0]octan-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methyl 3-hydroxy-2-tetradecyloctadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](COC(=O)C(CCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCC)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H]2OC[C@H]2O1 WCDYMMVGBZNUGB-ORPFKJIMSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- QQQSFSZALRVCSZ-UHFFFAOYSA-N triethoxysilane Chemical compound CCO[SiH](OCC)OCC QQQSFSZALRVCSZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
- B01D15/206—Packing or coating
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
Landscapes
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to the preparation method of DNA paper folding biological chromatography column and its applications in drug screening, it is not high that drug screening accuracy in the prior art can effectively be solved, the problem of process complexity, method is, activated silica gel and preparation carboxylated silica gel, the single stranded DNA that target spot length is 10 ~ 30 bp is modified, by M13mp18 ssDNA, 216 staple chains, target spot compound feeds intake in PCR instrument, 35 DEG C are dropped to from 60 DEG C with the rate of 6 DEG C/min, obtain the amidized DNA paper folding for being assembled with target spot compound, by carboxylated colloidal silica dispersion in PBS solution, DCC and NHS is added to mix, it adds and assembles the amidized DNA paper folding of target spot compound, it is stirred at room temperature, with PBS solution and milli-Q water, vacuum drying, then Dress column, homogenate and displacement fluid are PBS buffer solution to get DNA paper folding biological chromatography column is arrived, and the present invention gives full play to drug effect using easy, efficient, accuracy is high.
Description
Technical field
The present invention relates to chromatographic column, the preparation method of especially a kind of DNA paper folding biological chromatography column and its in drug screening
In application.
Background technique
Currently, be applied to drug screening model specifically include that the horizontal model of whole animal, the horizontal model of histoorgan and
Cell, molecular level model.
The screening of whole animal model drug can only screen limited sample, and copy with experimental animal
Pathological model it is extremely limited, there is significant limitation, poor efficiency and high cost etc. using whole animal model discrimination new drug
Drawback.The horizontal model of histoorgan overcomes the deficiency of whole animal model to a certain extent, but there are still small scale,
The disadvantages of low efficiency, limited reaction drug effect.Cell, molecular level medicaments sifting model be at present using more one kind
Method, but since detection method is limited to, it is extremely limited for the Testing index of drug screening, and the screening model accuracy is not
High (drug reaches cell rather than action target spot), screening process complicated (needing several days or even longer time), amount of samples are big
(need tens to several hundred milligrams).
2006, Rothemund was put forward for the first time a kind of completely new DNA self-assembling method --- DNA paper folding art
(Origami), and in Nature magazine with cover paper publishing.DNA paper folding have good biocompatibility, spatial addressability,
No cytotoxicity and shape and size can explication the advantages that, in addition to this, the distinguishing feature that DNA paper folding art also has has:
1) assembling process is simple；2) multidimensional nanostructure can accurately be assembled；3) assemblnig object type is various；4) can be used for studying
Field is extensive.
Since DNA paper folding has many advantages, such as that good biocompatibility, of uniform size, controlled shape, surface are easy modification,
It can be effectively improved Silica Surface, more receptors or compound is enable to be bonded to Silica Surface by DNA paper folding.But such as
What is anti-using the specificity between target spot (protein, biological enzyme, membrane receptor, nuclear receptor and other target spot compounds) and drug
It answers, realizes drug screening, and situations such as understanding drug distribution in vivo, metabolism and design and develop there is height
The drug molecule of activity, hypotoxicity is all of great significance, but so far there are no the technology public reporting.
Summary of the invention
For above situation, for the defect for overcoming the prior art, the purpose of the present invention is just to provide a kind of DNA paper folding biology
The preparation method of chromatographic column and its application in drug screening, can effectively solve in the prior art that drug screening accuracy is not
High, process complexity problem.
The technical solution that the present invention solves is, the method for the present invention the following steps are included:
1, activated silica gel and preparation carboxylated silica gel:
Silica gel is placed in the hydrochloric acid that volumetric concentration is 20% the 5-7 h that flows back, is washed with water to neutrality, in vacuum oven
In, 12-18 h(, which is dried in vacuo, at 55-65 DEG C stays overnight), at activated silica gel, activated silica gel is placed in dry toluene, is added
In gamma-aminopropyl-triethoxy-silane, under nitrogen protection, 100-120 DEG C of reflux 22-26 h washs 3 with toluene and ether respectively
Secondary, 55-65 DEG C of dry 12-18 h(is stayed overnight in a vacuum drying oven), at silicon amide glue, by amination silica gel ultrasonic disperse in
In 30 mL tetrahydrofurans, the succinic anhydride with gamma-aminopropyl-triethoxy-silane equimolar ratio is added, 24 h are stirred at room temperature, uses
Dehydrated alcohol washs 3 ~ 5 times, and 55-65 DEG C of dry 12-18 h(is stayed overnight in a vacuum drying oven), it is described at carboxylated silica gel
Silica gel partial size: 5 μm, aperture: 100-300 (commercial product such as: Qingdao Mei Gao Chemical Co., Ltd. product)；
2, DNA paper folding assembles target spot:
The single stranded DNA that target spot length is 10 ~ 30 bp to be modified, i.e., target spot compound contains one section of free DNA chain,
Staple chain has 216, wherein 5 ' ends of 12 staple chains are modified with one section of free single stranded DNA, on target spot compound
Modifying DNA chain it is complementary, 5 ' ends of 3 ~ 5 staple chains with amido modified, by M13mp18 ssDNA, 216 staple chains,
Target spot compound is by 1:(5-10): 1 molar ratio feeds intake in PCR instrument, is dropped with the rate of 6 DEG C/min from 60 DEG C by annealing
To 35 DEG C to get to the amidized DNA paper folding nanostructure for being assembled with target spot compound, the target spot is protein, life
Object enzyme, membrane receptor, nuclear receptor and other target spot compounds；
3, the DNA paper folding for assembling target spot is bonded carboxylated silica gel:
6 mg are added in the PBS solution that pH value is 7.2-7.4 in carboxylated silica gel ultrasonic disperse prepared by step 1
DCC and 5 mg NHS is mixed, and is added and is assembled amidized 4 mg of DNA paper folding of target spot compound, stirs 22- at room temperature
The PBS solution and ultrapure water that 26 h are 7.2-7.4 with pH value wash 3 times respectively, in a vacuum drying oven 55-65 DEG C of dry 12-
18 h(are stayed overnight), obtain DNA paper folding biological chromatography medium；
4, DNA paper folding biological chromatography column is made in dress column:
Stainless steel liquid-phase chromatographic column is taken, at 10 ~ 20 MPa, DNA paper folding biological chromatography medium prepared by step 3 is carried out
Fill column, the homogenate and displacement fluid for filling column be pH value be 7.2-7.4 PBS buffer solution to get to DNA paper folding biological chromatography
Column, the rust steel liquid-phase chromatographic column intracavity diameter are 4.6 mm, a length of 150 mm.
The chromatographic column is effective in drug screening.
The DNA paper folding chromatographic media provided by the invention for being suitable for drug screening, it is characterized in that using activated silica gel as matrix,
Using the good biocompatibility of DNA paper folding, spatial addressability, the advantages that object is various and assembling process is simple can be assembled by target
Point (protein, biological enzyme, membrane receptor, nuclear receptor and other target spot compounds) is assembled into DNA paper folding nanostructure, then by group
The DNA paper folding for having filled target spot compound is bonded on silica matrix and obtains novel biological chromatography medium.The object assembled
Can be as needed, assemble different compounds.Obtained biological chromatography medium is loaded in liquid-phase chromatographic column, one kind is obtained
DNA paper folding biological chromatography column.With using it is easy, efficiently, accuracy is high and gives full play to drug effect, economic and social benefit
It is huge.
Specific embodiment
The present invention will be further described in detail with reference to embodiments.
Embodiment 1
The present invention in specific implementation, is realized by following steps:
1, activated silica gel and preparation carboxylated silica gel:
Silica gel is placed in the hydrochloric acid that volumetric concentration is 20% and is flowed back 6 h, is washed with water to neutrality, in a vacuum drying oven,
15 h(are dried in vacuo at 60 DEG C to stay overnight), at activated silica gel, activated silica gel is placed in dry toluene, γ-aminopropyl is added
In triethoxysilane, under nitrogen protection, 110 DEG C of 24 h of reflux are washed 3 times with toluene and ether, respectively in vacuum oven
In 60 DEG C of 15 h(of drying stay overnight), at silicon amide glue, by amination silica gel ultrasonic disperse in 30 mL tetrahydrofurans, be added
With the succinic anhydride of gamma-aminopropyl-triethoxy-silane equimolar ratio, 24 h are stirred at room temperature, are washed 3 ~ 5 times with dehydrated alcohol, in
60 DEG C of 15 h(of drying are stayed overnight in vacuum oven), at carboxylated silica gel；
2, DNA paper folding assembles target spot:
The single stranded DNA that target spot length is 10 ~ 30 bp to be modified, i.e., target spot compound contains one section of free DNA chain,
Staple chain has 216, wherein 5 ' ends of 12 staple chains are modified with one section of free single stranded DNA, on target spot compound
Modifying DNA chain it is complementary, 5 ' ends of 3 ~ 5 staple chains with amido modified, by M13mp18 ssDNA, 216 staple chains,
Target spot compound feeds intake in PCR instrument by the molar ratio of 1:5:1, drops to 35 from 60 DEG C with the rate of 6 DEG C/min by annealing
DEG C to get to the amidized DNA paper folding nanostructure for being assembled with target spot compound；
3, the DNA paper folding for assembling target spot is bonded carboxylated silica gel:
6 mg are added in the PBS solution that pH value is 7.2-7.4 in carboxylated silica gel ultrasonic disperse prepared by step 1
DCC and 5 mg NHS is mixed, and is added and is assembled amidized 4 mg of DNA paper folding of target spot compound, stirs 24 at room temperature
The PBS solution and ultrapure water that h is 7.2-7.4 with pH value wash 3 times respectively, in a vacuum drying oven 60 DEG C of 15 h(mistakes of drying
Night), obtain DNA paper folding biological chromatography medium；
4, DNA paper folding biological chromatography column is made in dress column:
Stainless steel liquid-phase chromatographic column is taken, at 10 ~ 20 MPa, DNA paper folding biological chromatography medium prepared by step 3 is carried out
Fill column, the homogenate and displacement fluid for filling column be pH value be 7.2-7.4 PBS buffer solution to get to DNA paper folding biological chromatography
Column, the rust steel liquid-phase chromatographic column intracavity diameter are 4.6mm, a length of 150 mm.
Embodiment 2:
The present invention in specific implementation, is realized by following steps:
1, activated silica gel and preparation carboxylated silica gel:
Silica gel is placed in the hydrochloric acid that volumetric concentration is 20% and is flowed back 5 h, is washed with water to neutrality, in a vacuum drying oven,
18 h(are dried in vacuo at 55 DEG C to stay overnight), at activated silica gel, activated silica gel is placed in dry toluene, γ-aminopropyl is added
In triethoxysilane, under nitrogen protection, 100 DEG C of 26 h of reflux are washed 3 times with toluene and ether, respectively in vacuum oven
In 55 DEG C of 18 h(of drying stay overnight), at silicon amide glue, by amination silica gel ultrasonic disperse in 30 mL tetrahydrofurans, be added
With the succinic anhydride of gamma-aminopropyl-triethoxy-silane equimolar ratio, 24 h are stirred at room temperature, are washed 3 ~ 5 times with dehydrated alcohol, in
55 DEG C of 18 h(of drying are stayed overnight in vacuum oven), at carboxylated silica gel；
2, DNA paper folding assembles target spot:
The single stranded DNA that target spot length is 10 ~ 30 bp to be modified, i.e., target spot compound contains one section of free DNA chain,
Staple chain has 216, wherein 5 ' ends of 12 staple chains are modified with one section of free single stranded DNA, on target spot compound
Modifying DNA chain it is complementary, 5 ' ends of 3 ~ 5 staple chains with amido modified, by M13mp18 ssDNA, 216 staple chains,
Target spot compound feeds intake in PCR instrument by the molar ratio of 1:8:1, drops to 35 from 60 DEG C with the rate of 6 DEG C/min by annealing
DEG C to get to the amidized DNA paper folding nanostructure for being assembled with target spot compound, the target spot be protein, biological enzyme,
Membrane receptor, nuclear receptor and other target spot compounds；
3, the DNA paper folding for assembling target spot is bonded carboxylated silica gel:
6 mg are added in the PBS solution that pH value is 7.2-7.4 in carboxylated silica gel ultrasonic disperse prepared by step 1
DCC and 5 mg NHS is mixed, and is added and is assembled amidized 4 mg of DNA paper folding of target spot compound, stirs 22- at room temperature
The PBS solution and ultrapure water that 26 h are 7.2-7.4 with pH value wash 3 times respectively, in a vacuum drying oven 55 DEG C of 18 h of drying
(overnight) obtains DNA paper folding biological chromatography medium；
4, DNA paper folding biological chromatography column is made in dress column:
Stainless steel liquid-phase chromatographic column is taken, at 10 ~ 20 MPa, DNA paper folding biological chromatography medium prepared by step 3 is carried out
Fill column, the homogenate and displacement fluid for filling column be pH value be 7.2-7.4 PBS buffer solution to get to DNA paper folding biological chromatography
Column, the rust steel liquid-phase chromatographic column intracavity diameter are 4.6 mm, a length of 150 mm.
Embodiment 3
1, activated silica gel and preparation carboxylated silica gel:
Silica gel is placed in the hydrochloric acid that volumetric concentration is 20% the 5-7 h that flows back, is washed with water to neutrality, in vacuum oven
In, it is dried in vacuo 12 h(at 65 DEG C and stays overnight), at activated silica gel, activated silica gel is placed in dry toluene, γ-ammonia third is added
In ethyl triethoxy silicane alkane, under nitrogen protection, 120 DEG C of 22 h of reflux are washed 3 times with toluene and ether, respectively in vacuum drying
65 DEG C of 12 h(of drying are stayed overnight in case), add by amination silica gel ultrasonic disperse in 30 mL tetrahydrofurans at silicon amide glue
Enter the succinic anhydride with gamma-aminopropyl-triethoxy-silane equimolar ratio, 24 h be stirred at room temperature, is washed 3 ~ 5 times with dehydrated alcohol,
65 DEG C of 12 h(of drying are stayed overnight in a vacuum drying oven), at carboxylated silica gel；
2, DNA paper folding assembles target spot:
The single stranded DNA that target spot length is 10 ~ 30 bp to be modified, i.e., target spot compound contains one section of free DNA chain,
Staple chain has 216, wherein 5 ' ends of 12 staple chains are modified with one section of free single stranded DNA, on target spot compound
Modifying DNA chain it is complementary, 5 ' ends of 3 ~ 5 staple chains with amido modified, by M13mp18 ssDNA, 216 staple chains,
Target spot compound is by 1:(5-10): 1 molar ratio feeds intake in PCR instrument, is dropped with the rate of 6 DEG C/min from 60 DEG C by annealing
To 35 DEG C to get to the amidized DNA paper folding nanostructure for being assembled with target spot compound, the target spot is protein, life
Object enzyme, membrane receptor, nuclear receptor and other target spot compounds；
3, the DNA paper folding for assembling target spot is bonded carboxylated silica gel:
6 mg are added in the PBS solution that pH value is 7.2-7.4 in carboxylated silica gel ultrasonic disperse prepared by step 1
DCC and 5 mg NHS is mixed, and is added and is assembled amidized 4 mg of DNA paper folding of target spot compound, stirs 22- at room temperature
The PBS solution and ultrapure water that 26 h are 7.2-7.4 with pH value wash 3 times respectively, in a vacuum drying oven 65 DEG C of 12 h of drying
(overnight) obtains DNA paper folding biological chromatography medium；
4, DNA paper folding biological chromatography column is made in dress column:
Stainless steel liquid-phase chromatographic column is taken, at 10 ~ 20 MPa, DNA paper folding biological chromatography medium prepared by step 3 is carried out
Fill column, the homogenate and displacement fluid for filling column be pH value be 7.2-7.4 PBS buffer solution to get to DNA paper folding biological chromatography
Column, the rust steel liquid-phase chromatographic column intracavity diameter are 4.6 mm, a length of 150 mm.
The DNA paper folding biological chromatography column that above-described embodiment provides is effective in drug screening.
The building of DNA paper folding refers to Paul W. K. Rothemund(Rothemund P W. in 2006 in the present invention
Folding DNA to create nanoscale shapes and patterns [J]. Nature, 2006, 440:
297 ~ 302) building of rectangle paper folding in the article delivered, the single stranded circle DNA of M13 bacteriophage are 216 long as scaffold chain
Short different short chain DNA is as staple chain.The present invention will in Paul W. K. Rothemund article number be 4,13,55,
63,102,106,116,123,162,170,208,212 etc. 12 staple chains use 20 base sequences at 3 ' ends
(ATTCTACTTG AGAGAGCGAC) is modified, and 3 staple chains such as number 100,105,110 use amino at 5 ' ends
(NH2-C6-TTTTTTTTTT) it is modified.The staple chain of other numbers is unmodified, no longer lists.
4 GAGCCGCCCC ACCACCGGAA CCGCGACGGA AAATTCTACT TGAGAGAGCG AC
13 ATCGGCTGCG AGCATGTAGA AACCTATCAT ATATTCTACT TGAGAGAGCG AC
55 CACCAGAGTT CGGTCATAGC CCCCGCCAGC AAATTCTACT TGAGAGAGCG AC
63 CAAGCAAGAC GCGCCTGTTT ATCAAGAATC GCATTCTACT TGAGAGAGCG AC
102 ACAAACAATT TTAATCAGTA GCGACAGATC GATAGCATTC TACTTGAGAG AGCGAC
106 TATAGAAGTT TTCGACAAAA GGTAAAGTAG AGAATAATTC TACTTGAGAG AGCGAC
116 TTCGCCATTG CCGGAAACCA GGCATTAAAT CAATTCTACT TGAGAG AGCG AC
123 TTTTAATTGC CCGAAAGACT TCAAAACACT ATATTCTACT TGAGAGAGCG AC
162 CAGCTGGCGG ACGACGACAG TATCGTAGCC AGATTCTACT TGAGAGAGCG AC
170 TACCTTTAAG GTCTTTACCC TGACAAAGAA GTATTCTACT TGAGAGAGCG AC
208 CACGACGTTT TTGTAATGGG ATAGGTCAAA ACGGCGATTC TACTTGAGAG AGCGAC
212 ATATAATGTT TTCATTGAAT CCCCCTCAAA TCGTCAATTC TACTTGAGAG AGCGAC
100 NH2-C6-TTTTTTTTTT TTTTTATAAG TATAGCCCGG CCGTCGAG
105 NH2-C6-TTTTTTTTTT GCGCATTATT TTGCTTATCC GGTATTCTAA ATCAGA
110 NH2-C6-TTTTTTTTTT GATGGCAATT TTAATCAATA TCTGGTCACA AATATC
The above-mentioned embodiment provided is only for illustrating a specific embodiment of the invention, is not intended to limit the invention
Protection scope, it is all in itself it is identical with technical solution of the present invention it is various improve, transformation or substitution belong to the present invention
Protection scope, it is very good that the present invention is tested its effect, and easy to use, accuracy is high, and high-efficient, relevant information is as follows:
Experiment 1:
For the present invention by taking target spot compound is bovine serum albumin(BSA) as an example, specific experiment situation is as follows:
DNA paper folding biological chromatography column (target spot compound therein is bovine serum albumin(BSA)) in this experiment using preparation is to Ah
Department woods is analyzed under conditions of phosphate buffer is mobile phase, and aspirin is in new bio chromatographic column of the present invention
With a hook at the end on (using bovine serum albumin(BSA) as target spot), retention time is 3.937 min；Aspirin does not have on silica gel chromatographic column
Retain, with etoh solvent appearance.Chromatographic condition is as follows: mobile phase is the phosphate buffer of 20mM, and flow velocity is 0.8 mL/
Min, 30 DEG C of column temperature, the concentration of aspirin is 0.1 mg/mL, and sampling volume is 20 μ L.
Aspirin produces the spy of receptor-ligand with BSA on Novel DNA paper folding biological chromatography column prepared by the present invention
Different affinity interaction, and aspirin does not retain on silica gel chromatographic column, with solvent appearance.Aspirin is in two chromatographic columns
The difference of upper retention time, illustrate silica gel itself be to aspirin it is uncensored, in Novel DNA paper folding prepared by the present invention
Reservation on biological chromatography column is its specific effect between BSA.Compared to directly biologically active BSA is bonded to
The method of drug is screened or is analyzed on inorganic silica gel surface, and method provided by the present invention is by being assembled into DNA paper folding for BSA
On, then be bonded on carboxylated silica gel by the effect of EDC and NHS, nothing is effectively improved using the biocompatibility of DNA paper folding
The surface of machine silica gel can effectively keep the bioactivity of BSA.And compared to traditional medicaments sifting model, system of the present invention
Standby Novel DNA paper folding biological chromatography column can be analyzed directly using high performance liquid chromatograph, so that this screening technique is more
Accurately (drug go directly action target spot), easy (can be analyzed within 15 min), detection method is sensitive, and (sample volume is 20 μ
G), analysis result is more intuitive, and also environmental protection is easy to get the mobile phase used.In addition to this, drug sieve provided by the present invention
Modeling type is for the first time to share DNA paper folding and liquid chromatograph in drug screening, therefore drug screening provided by the present invention
Model is more innovative.
Experiment 2:
The DNA paper folding biological chromatography column (target spot therein that the present invention is prepared using target spot compound as the lipase of biological enzyme
Compound is lipase) scutelloside is analyzed under conditions of phosphate buffer is mobile phase.Scutelloside is in the present invention
With a hook at the end on biological chromatography column (using lipase as target spot), retention time is 9.733 min；Aspirin is on silica gel chromatographic column
Do not retain, with solvent methanol appearance.Chromatographic condition is as follows: mobile phase is the phosphate buffer of 20 mM, flow velocity 0.4
ML/min, column temperature are 30 DEG C, and the concentration of scutelloside is 0.1mg/mL, and sampling volume is 20 μ L.
Scutelloside produces the special of receptor-ligand with lipase on DNA paper folding biological chromatography column prepared by the present invention
Affinity interaction, and scutelloside does not retain on silica gel chromatographic column, with solvent appearance.Scutelloside retains in two chromatographic columns
The difference of time, illustrate silica gel itself be to scutelloside it is uncensored, on DNA paper folding biological chromatography column prepared by the present invention
Reservation be its specific effect between lipase.It will be biologically active lipase bonded to inorganic silicon compared to directly
The method of drug is screened or is analyzed on glue surface, method provided by the present invention by the way that lipase is assembled into DNA paper folding, then
It is bonded on carboxylated silica gel by the effect of EDC and NHS, effectively improves inorganic silicon using the biocompatibility of DNA paper folding
The surface of glue can effectively keep the bioactivity of lipase.And compared to traditional medicaments sifting model, present invention preparation
Novel DNA paper folding biological chromatography column can directly be analyzed using high performance liquid chromatograph so that this screening technique is more quasi-
Really (drug go directly action target spot), easy (can be analyzed within 15 min), detection method is sensitive, and (sample volume is 20 μ
G), analysis result is more intuitive, and the mobile phase used is nontoxic, is easy to get.In addition to this, drug screening provided by the present invention
Model is for the first time to share DNA paper folding and liquid chromatograph in drug screening, therefore drug sieve modeling provided by the present invention
Type is more innovative.
In conclusion the present invention relates to a kind of preparation of DNA paper folding biological chromatography column, and utilize the target spot (egg of its assembling
White matter, biological enzyme, membrane receptor, nuclear receptor and other target spot compounds) and drug between specificity realize the screening of drug.
Present invention utilizes the efficient, easy of the plurality of advantages of DNA paper folding and liquid chromatogram, compared to cell used at present, point
Sub horizontal medicaments sifting model, this drug screening method have more the through action target spot of accuracy drug, make full use of drug big
Curative effect is improved greatly, and utilization ratio of drug improves dozens or even hundreds of times, and at low cost, amount of samples is reduced thousands of times, has very strong
Use value, economic and social benefit is huge.
SEQUENCE LISTING
<110>Zhengzhou University
<120>a kind of preparation method of DNA paper folding biological chromatography column and its application in drug screening
<160> 15
<210> 4
<211> 52
<212> DNA
<213>artificial sequence
<400> 4
GAGCCGCCCC ACCACCGGAA CCGCGACGGA AAATTCTACT TGAGAGAGCG AC 52
<210> 13
<211> 52
<212> DNA
<213>artificial sequence
<400> 13
ATCGGCTGCG AGCATGTAGA AACCTATCAT ATATTCTACT TGAGAGAGCG AC 52
<210> 55
<211> 52
<212> DNA
<213>artificial sequence
<400> 55
CACCAGAGTT CGGTCATAGC CCCCGCCAGC AAATTCTACT TGAGAGAGCG AC 52
<210> 63
<211> 52
<212> DNA
<213>artificial sequence
<400> 63
CAAGCAAGAC GCGCCTGTTT ATCAAGAATC GCATTCTACT TGAGAGAGCG AC 52
<210> 102
<211> 56
<212> DNA
<213>artificial sequence
<400> 102
ACAAACAATT TTAATCAGTA GCGACAGATC GATAGCATTC TACTTGAGAG AGCGAC 56
<210> 106
<211> 56
<212> DNA
<213>artificial sequence
<400> 106
TATAGAAGTT TTCGACAAAA GGTAAAGTAG AGAATAATTC TACTTGAGAG AGCGAC 56
<210> 116
<211> 52
<212> DNA
<213>artificial sequence
<400> 116
TTCGCCATTG CCGGAAACCA GGCATTAAAT CAATTCTACT TGAGAG AGCG AC 52
<210> 123
<211> 52
<212> DNA
<213>artificial sequence
<400> 123
TTTTAATTGC CCGAAAGACT TCAAAACACT ATATTCTACT TGAGAGAGCG AC 52
<210> 162
<211> 52
<212> DNA
<213>artificial sequence
<400> 162
CAGCTGGCGG ACGACGACAG TATCGTAGCC AGATTCTACT TGAGAGAGCG AC 52
<210> 170
<211> 52
<212> DNA
<213>artificial sequence
<400> 170
TACCTTTAAG GTCTTTACCC TGACAAAGAA GTATTCTACT TGAGAGAGCG AC 52
<210> 208
<211> 56
<212> DNA
<213>artificial sequence
<400> 208
CACGACGTTT TTGTAATGGG ATAGGTCAAA ACGGCGATTC TACTTGAGAG AGCGAC 56
<210> 212
<211> 56
<212> DNA
<213>artificial sequence
<400> 212
ATATAATGTT TTCATTGAAT CCCCCTCAAA TCGTCAATTC TACTTGAGAG AGCGAC 56
<210> 100
<211> 38
<212> DNA
<213>artificial sequence
<400> 100
NH2-C6-TTTTTTTTTT TTTTTATAAG TATAGCCCGG CCGTCGAG 38
<210> 105
<211> 46
<212> DNA
<213>artificial sequence
<400> 105
NH2-C6-TTTTTTTTTT GCGCATTATT TTGCTTATCC GGTATTCTAA ATCAGA 46
<210> 110
<211> 46
<212> DNA
<213>artificial sequence
<400> 110
NH2-C6-TTTTTTTTTT GATGGCAATT TTAATCAATA TCTGGTCACA AATATC 46
Claims (5)
1. a kind of preparation method of DNA paper folding biological chromatography column, which comprises the following steps:
(1), activated silica gel and preparation carboxylated silica gel:
Silica gel is placed in the hydrochloric acid that volumetric concentration is 20% the 5-7 h that flows back, is washed with water to neutrality, in a vacuum drying oven, in
It is dried in vacuo 12-18 h at 55-65 DEG C activated silica gel is placed in dry toluene at activated silica gel, γ-aminopropyl three is added
In Ethoxysilane, under nitrogen protection, 100-120 DEG C of reflux 22-26 h is washed 3 times respectively with toluene and ether, dry in vacuum
55-65 DEG C of dry 12-18 h in dry case, at silicon amide glue, by amination silica gel ultrasonic disperse in 30 mL tetrahydrofurans,
The succinic anhydride with gamma-aminopropyl-triethoxy-silane equimolar ratio is added, 24 h are stirred at room temperature, wash 3 ~ 5 with dehydrated alcohol
It is secondary, 55-65 DEG C of dry 12-18 h in a vacuum drying oven, at carboxylated silica gel, described silica gel partial size: 5 μm, aperture:
100-300 Å；
(2), DNA paper folding assembles target spot:
The single stranded DNA that target spot length is 10 ~ 30 bp is modified, i.e., target spot compound contains one section of free DNA chain, stapler
Nail chain has 216, wherein 5 ' ends of 12 staple chains are modified with one section of free single stranded DNA, with repairing on target spot compound
Adorn that DNA chain is complementary, 5 ' ends of 3 ~ 5 staple chains are with amido modified, by M13mp18 ssDNA, 216 staple chains, target spots
Compound is by 1:(5-10): 1 molar ratio feeds intake in PCR instrument, drops to 35 from 60 DEG C with the rate of 6 DEG C/min by annealing
DEG C to get to the amidized DNA paper folding nanostructure for being assembled with target spot compound, the target spot be protein, biological enzyme,
Membrane receptor, nuclear receptor and other target spot compounds；
(3), the DNA paper folding for assembling target spot is bonded carboxylated silica gel:
6 mg DCC and 5 are added in the PBS solution that pH value is 7.2-7.4 in carboxylated silica gel ultrasonic disperse prepared by step 1
Mg NHS is mixed, and is added and is assembled amidized 4 mg of DNA paper folding of target spot compound, stirs 22-26 h at room temperature, is used
PH value is that the PBS solution of 7.2-7.4 and ultrapure water wash 3 times respectively, and 55-65 DEG C of dry 12-18 h, obtains in a vacuum drying oven
DNA paper folding biological chromatography medium；
(4), DNA paper folding biological chromatography column is made in dress column:
Stainless steel liquid-phase chromatographic column is taken, at 10 ~ 20 MPa, DNA paper folding biological chromatography medium prepared by step 3 is filled
Column, the homogenate and displacement fluid for filling column be pH value be 7.2-7.4 PBS buffer solution to get to DNA paper folding biological chromatography
Column, the stainless steel liquid-phase chromatographic column intracavity diameter are 4.6 mm, a length of 150 mm.
2. the preparation method of DNA paper folding biological chromatography column according to claim 1, which is characterized in that by following steps reality
It is existing:
(1), activated silica gel and preparation carboxylated silica gel:
Silica gel is placed in the hydrochloric acid that volumetric concentration is 20% 6 h that flow back, is washed with water to neutrality, in a vacuum drying oven, in 60
It is dried in vacuo 15 h at DEG C, at activated silica gel, activated silica gel is placed in dry toluene, gamma-aminopropyl-triethoxy silicon is added
In alkane, under nitrogen protection, 110 DEG C of 24 h of reflux are washed 3 times, 60 DEG C of dryings in a vacuum drying oven respectively with toluene and ether
15 h by amination silica gel ultrasonic disperse in 30 mL tetrahydrofurans, are added and three ethoxy of γ-aminopropyl at silicon amide glue
The succinic anhydride of base silane equimolar ratio, is stirred at room temperature 24 h, is washed 3 ~ 5 times, in a vacuum drying oven 60 DEG C with dehydrated alcohol
Dry 15 h, at carboxylated silica gel；
(2), DNA paper folding assembles target spot:
The single stranded DNA that target spot length is 10 ~ 30 bp is modified, i.e., target spot compound contains one section of free DNA chain, stapler
Nail chain has 216, wherein 5 ' ends of 12 staple chains are modified with one section of free single stranded DNA, with repairing on target spot compound
Adorn that DNA chain is complementary, 5 ' ends of 3 ~ 5 staple chains are with amido modified, by M13mp18 ssDNA, 216 staple chains, target spots
Compound is by 1:(5-10): 1 molar ratio feeds intake in PCR instrument, drops to 35 from 60 DEG C with the rate of 6 DEG C/min by annealing
DEG C to get to the amidized DNA paper folding nanostructure for being assembled with target spot compound；
(3), the DNA paper folding for assembling target spot is bonded carboxylated silica gel:
6 mg DCC and 5 are added in the PBS solution that pH value is 7.2-7.4 in carboxylated silica gel ultrasonic disperse prepared by step 1
Mg NHS is mixed, and is added and is assembled amidized 4 mg of DNA paper folding of target spot compound, stirs 24 h at room temperature, use pH
Value is that the PBS solution of 7.2-7.4 and ultrapure water wash 3 times respectively, and 60 DEG C of 15 h of drying, obtain DNA paper folding in a vacuum drying oven
Biological chromatography medium；
(4), DNA paper folding biological chromatography column is made in dress column:
Stainless steel liquid-phase chromatographic column is taken, at 10 ~ 20 MPa, DNA paper folding biological chromatography medium prepared by step 3 is filled
Column, the homogenate and displacement fluid for filling column be pH value be 7.2-7.4 PBS buffer solution to get to DNA paper folding biological chromatography
Column, the stainless steel liquid-phase chromatographic column intracavity diameter are 4.6 mm, a length of 150 mm.
3. the preparation method of DNA paper folding biological chromatography column according to claim 1, which is characterized in that by following steps reality
It is existing:
(1), activated silica gel and preparation carboxylated silica gel:
Silica gel is placed in the hydrochloric acid that volumetric concentration is 20% 5h that flows back, is washed with water to neutrality, in a vacuum drying oven, in 55
It is dried in vacuo 18 h at DEG C, at activated silica gel, activated silica gel is placed in dry toluene, gamma-aminopropyl-triethoxy silicon is added
In alkane, under nitrogen protection, 100 DEG C of 26 h of reflux are washed 3 times, 55 DEG C of dryings in a vacuum drying oven respectively with toluene and ether
18 h by amination silica gel ultrasonic disperse in 30 mL tetrahydrofurans, are added and three ethoxy of γ-aminopropyl at silicon amide glue
The succinic anhydride of base silane equimolar ratio, is stirred at room temperature 24 h, is washed 3 ~ 5 times, in a vacuum drying oven 55 DEG C with dehydrated alcohol
Dry 18 h, at carboxylated silica gel；
(2), DNA paper folding assembles target spot:
The single stranded DNA that target spot length is 10 ~ 30 bp is modified, i.e., target spot compound contains one section of free DNA chain, stapler
Nail chain has 216, wherein 5 ' ends of 12 staple chains are modified with one section of free single stranded DNA, with repairing on target spot compound
Adorn that DNA chain is complementary, 5 ' ends of 3 ~ 5 staple chains are with amido modified, by M13mp18 ssDNA, 216 staple chains, target spots
Compound is by 1:(5-10): 1 molar ratio feeds intake in PCR instrument, drops to 35 from 60 DEG C with the rate of 6 DEG C/min by annealing
DEG C to get to the amidized DNA paper folding nanostructure for being assembled with target spot compound, the target spot be protein, biological enzyme,
Membrane receptor, nuclear receptor and other target spot compounds；
(3), the DNA paper folding for assembling target spot is bonded carboxylated silica gel:
6 mg DCC and 5 are added in the PBS solution that pH value is 7.2-7.4 in carboxylated silica gel ultrasonic disperse prepared by step 1
Mg NHS is mixed, and is added and is assembled amidized 4 mg of DNA paper folding of target spot compound, stirs 22-26 h at room temperature, is used
PH value is the PBS solution of 7.2-7.4 and ultrapure water washs 3 times respectively, and 55 DEG C of 18 h of drying, obtain DNA folding in a vacuum drying oven
Paper biological chromatography medium；
(4), DNA paper folding biological chromatography column is made in dress column:
Stainless steel liquid-phase chromatographic column is taken, at 10 ~ 20 MPa, DNA paper folding biological chromatography medium prepared by step 3 is filled
Column, the homogenate and displacement fluid for filling column be pH value be 7.2-7.4 PBS buffer solution to get to DNA paper folding biological chromatography
Column, the stainless steel liquid-phase chromatographic column intracavity diameter are 4.6 mm, a length of 150 mm.
4. the preparation method of DNA paper folding biological chromatography column according to claim 1, which is characterized in that by following steps reality
It is existing:
(1), activated silica gel and preparation carboxylated silica gel:
Silica gel is placed in the hydrochloric acid that volumetric concentration is 20% the 5-7 h that flows back, is washed with water to neutrality, in a vacuum drying oven, in
It is dried in vacuo 12 h at 65 DEG C, at activated silica gel, activated silica gel is placed in dry toluene, gamma-aminopropyl-triethoxy is added
In silane, under nitrogen protection, 120 DEG C of 22 h of reflux are washed 3 times respectively with toluene and ether, are done for 65 DEG C in a vacuum drying oven
Dry 12 h by amination silica gel ultrasonic disperse in 30 mL tetrahydrofurans, is added and three second of γ-aminopropyl at silicon amide glue
The succinic anhydride of oxysilane equimolar ratio, is stirred at room temperature 24 h, washs 3 ~ 5 times with dehydrated alcohol, and in a vacuum drying oven 65
DEG C dry 12 h, at carboxylated silica gel；
(2), DNA paper folding assembles target spot:
The single stranded DNA that target spot length is 10 ~ 30 bp is modified, i.e., target spot compound contains one section of free DNA chain, stapler
Nail chain has 216, wherein 5 ' ends of 12 staple chains are modified with one section of free single stranded DNA, with repairing on target spot compound
Adorn that DNA chain is complementary, 5 ' ends of 3 ~ 5 staple chains are with amido modified, by M13mp18 ssDNA, 216 staple chains, target spots
Compound is by 1:(5-10): 1 molar ratio feeds intake in PCR instrument, drops to 35 from 60 DEG C with the rate of 6 DEG C/min by annealing
DEG C to get to the amidized DNA paper folding nanostructure for being assembled with target spot compound, the target spot be protein, biological enzyme,
Membrane receptor, nuclear receptor and other target spot compounds；
(3), the DNA paper folding for assembling target spot is bonded carboxylated silica gel:
6 mg DCC and 5 are added in the PBS solution that pH value is 7.2-7.4 in carboxylated silica gel ultrasonic disperse prepared by step 1
Mg NHS is mixed, and is added and is assembled amidized 4 mg of DNA paper folding of target spot compound, stirs 22-26 h at room temperature, is used
PH value is the PBS solution of 7.2-7.4 and ultrapure water washs 3 times respectively, and 65 DEG C of 12 h of drying, obtain DNA folding in a vacuum drying oven
Paper biological chromatography medium；
(4), DNA paper folding biological chromatography column is made in dress column:
Stainless steel liquid-phase chromatographic column is taken, at 10 ~ 20 MPa, DNA paper folding biological chromatography medium prepared by step 3 is filled
Column, the homogenate and displacement fluid for filling column be pH value be 7.2-7.4 PBS buffer solution to get to DNA paper folding biological chromatography
Column, the stainless steel liquid-phase chromatographic column intracavity diameter are 4.6 mm, a length of 150 mm.
5. application of the DNA paper folding biological chromatography column of claim 1 the method preparation in drug screening.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710401978.2A CN107233750B (en) | 2017-06-01 | 2017-06-01 | A kind of preparation method of DNA paper folding biological chromatography column and its application in drug screening |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710401978.2A CN107233750B (en) | 2017-06-01 | 2017-06-01 | A kind of preparation method of DNA paper folding biological chromatography column and its application in drug screening |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107233750A CN107233750A (en) | 2017-10-10 |
| CN107233750B true CN107233750B (en) | 2019-03-29 |
Family
ID=59984706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710401978.2A Expired - Fee Related CN107233750B (en) | 2017-06-01 | 2017-06-01 | A kind of preparation method of DNA paper folding biological chromatography column and its application in drug screening |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107233750B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109946409B (en) * | 2019-03-21 | 2022-07-26 | 山东师范大学 | Solid-phase extraction affinity column for estrogen interferent and preparation method and application thereof |
| CN110308233A (en) * | 2019-06-28 | 2019-10-08 | 江苏大学 | The preparation method and applications of P- glycoprotein biology affinity chromatographic column |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104133053A (en) * | 2014-05-28 | 2014-11-05 | 上海纳米技术及应用国家工程研究中心有限公司 | Detection method using DNA nano-origami structure as signal amplification probe |
| CN104406945A (en) * | 2014-11-19 | 2015-03-11 | 上海纳米技术及应用国家工程研究中心有限公司 | Fluorescent quantitative analysis method utilizing DNA (deoxyribonucleic acid) nanometer paper folding structure |
| CN106771375A (en) * | 2016-12-27 | 2017-05-31 | 上海纳米技术及应用国家工程研究中心有限公司 | The detection method that a kind of interface DNA patterns are varied with temperature |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6209517B2 (en) * | 2011-08-26 | 2017-10-04 | ベコイ ナノメディシンズ リミテッドＶｅｃｏｙ Ｎａｎｏｍｅｄｉｃｉｎｅｓ Ｌｔｄ． | Synthetic and pharmaceutical compositions for capturing pathogens |
| WO2014200933A1 (en) * | 2013-06-12 | 2014-12-18 | Arizona Board Of Regents On Behalf Of Arizona State University | Obtaining information from single cells within populations using dna origami nanostructures |
| BR112017005823B1 (en) * | 2014-09-29 | 2023-03-28 | Archer-Daniels-Midland Company | PROCESS FOR PREPARING AN EXTRACT |
-
2017
- 2017-06-01 CN CN201710401978.2A patent/CN107233750B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104133053A (en) * | 2014-05-28 | 2014-11-05 | 上海纳米技术及应用国家工程研究中心有限公司 | Detection method using DNA nano-origami structure as signal amplification probe |
| CN104406945A (en) * | 2014-11-19 | 2015-03-11 | 上海纳米技术及应用国家工程研究中心有限公司 | Fluorescent quantitative analysis method utilizing DNA (deoxyribonucleic acid) nanometer paper folding structure |
| CN106771375A (en) * | 2016-12-27 | 2017-05-31 | 上海纳米技术及应用国家工程研究中心有限公司 | The detection method that a kind of interface DNA patterns are varied with temperature |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107233750A (en) | 2017-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Falsey et al. | Peptide and small molecule microarray for high throughput cell adhesion and functional assays | |
| US7179638B2 (en) | Microarrays and their manufacture by slicing | |
| US6887701B2 (en) | Microarrays and their manufacture | |
| Bertone et al. | Advances in functional protein microarray technology | |
| KR100784437B1 (en) | Composition of Sol for Sol-Gel Biochip to Immobilize Probe On Substrate Without Surface Treatment and Method for Screening Thereof | |
| Díaz-Mochón et al. | Microarray platforms for enzymatic and cell-based assays | |
| Xu et al. | Protein and chemical microarrays—powerful tools for proteomics | |
| US20020015952A1 (en) | Microarrays and their manufacture by slicing | |
| Kusnezow et al. | Antibody microarray‐based profiling of complex specimens: systematic evaluation of labeling strategies | |
| CN107233750B (en) | A kind of preparation method of DNA paper folding biological chromatography column and its application in drug screening | |
| US20030044389A1 (en) | Microarrays for cell phenotyping and manipulation | |
| WO2006047791A2 (en) | Dna-templated combinatorial library device and method for use | |
| Kersten et al. | Multiplex approaches in protein microarray technology | |
| EP2229402B1 (en) | Synthetic peptides immuno-reactive with rheumatoid arthritis auto-antibodies | |
| JP2010501845A (en) | Active carrier, its production and its use | |
| US20130053271A1 (en) | Self-Assembled Bead-Based Multiplexed Assay For Antigen-Specific Antibodies | |
| Lin et al. | Controlling Surface Wettability for Automated In Situ Array Synthesis and Direct Bioscreening | |
| Doran et al. | A liquid array platform for the multiplexed analysis of synthetic molecule–protein interactions | |
| WO2014031984A1 (en) | Immunological detection methods and compositions | |
| Li et al. | Combinatorial peptide microarray synthesis based on microfluidic impact printing | |
| CN103409809A (en) | Small molecule drug screening chip, construction method and application thereof | |
| Andresen et al. | Peptide microarrays with site-specifically immobilized synthetic peptides for antibody diagnostics | |
| Matson | Applying genomic and proteomic microarray technology in drug discovery | |
| WO2002010761A1 (en) | Microarrays and their manufacture by slicing | |
| US8153367B2 (en) | Amplified array analysis system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 450001 Zhengzhou science and Technology Development Zone, Henan, No. 100 science Avenue Applicant after: Zhengzhou University Address before: 450001 science avenue of Zhengzhou high tech Development Zone, Zhengzhou, Henan Province, No. Applicant before: Zhengzhou University |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190329 Termination date: 20200601 |